ESMO PRECEPTORSHIP PROGRAMME
HEREDITARY CANCER GENETICS
Multidisciplinary management, standards of care and future perspectives

Paris, France
29-30 September 2023

CO-CHAIRS
Judith Balmaña, Spain
Nicoline Hoogerbrugge, Netherlands

SPEAKERS
Stefan Aretz, Germany
Matteo Lambertini, Italy
Marjolijn Ligtenberg, Netherlands
Carla Oliveira, Portugal
Rolf Sijmons, Netherlands
Marc Tischkowitz, United Kingdom

LEARNING OBJECTIVES

- To learn about the best clinical practice in the multidisciplinary management of hereditary cancer syndromes
- To understand the molecular basis and heterogeneity of the genetic susceptibility to develop cancer
- To learn how to recognize, diagnose, treat and provide prevention recommendations to patients with a germline genetic susceptibility

Friday, 29 September 2023

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Chair:</th>
</tr>
</thead>
<tbody>
<tr>
<td>09:00-09:15</td>
<td>Welcome and introduction</td>
<td>Judith Balmaña, ES Nicoline Hoogerbrugge, NL</td>
</tr>
<tr>
<td>09:15-10:55</td>
<td>SESSION 1 Challenges in hereditary cancer in 2023</td>
<td>Chair: Judith Balmaña, ES</td>
</tr>
<tr>
<td>30’</td>
<td>Overview of the clinical challenges in hereditary cancer: Identification, treatment and prevention. The role of ERN-GENTURIS network in Europe</td>
<td>Nicoline Hoogerbrugge, NL</td>
</tr>
<tr>
<td>30’</td>
<td>Challenges of tumor sequencing, exome sequencing and liquid biopsies: Interpretation of pathogenicity, incidental findings, ruling out a germline origin</td>
<td>Marjolijn Ligtenberg, NL</td>
</tr>
<tr>
<td>30’</td>
<td>Challenges of risk communication in hereditary cancer</td>
<td>Rolf Sijmons, NL</td>
</tr>
<tr>
<td>10’</td>
<td>Discussion</td>
<td>Faculty</td>
</tr>
<tr>
<td>10:55-11:25</td>
<td>Coffee break</td>
<td></td>
</tr>
<tr>
<td>11:25-13:05</td>
<td>SESSION 2 Hereditary gastrointestinal cancer</td>
<td>Chair: Nicoline Hoogerbrugge, NL</td>
</tr>
<tr>
<td>30’</td>
<td>Hereditary gastric cancer</td>
<td>Carla Oliveira, PT</td>
</tr>
<tr>
<td>30’</td>
<td>What an oncologist needs to know about polyposis and colorectal cancer germline susceptibility</td>
<td>Stefan Aretz, DE</td>
</tr>
<tr>
<td>30’</td>
<td>How to identify Lynch syndrome patients when treating patients with CRC</td>
<td>Judith Balmaña, ES</td>
</tr>
<tr>
<td>10’</td>
<td>Discussion</td>
<td>Faculty</td>
</tr>
<tr>
<td>13:05-14:05</td>
<td>Lunch</td>
<td></td>
</tr>
<tr>
<td>---</td>
<td>---</td>
<td></td>
</tr>
</tbody>
</table>
| 14:05-15:05 | **SESSION 3**  
Hereditary prostate and pancreatic cancer: What an oncologist needs to know  
Chair: Nicoline Hoogerbrugge, NL |
| 105’ | 30’ Germline susceptibility to prostate cancer: What genes to test, when, and why?  
Rolf Sijmons, NE |
|  | 30’ Advances in hereditary pancreatic cancer  
Marc Tischkowitz, UK |
|  | 45’ Participants clinical case discussion (3x15’)  
Faculty |
| 15:00-16:00 | Coffee break |
| 16:00-17:00 | **SESSION 4**  
Challenges in identification of hereditary susceptibility  
Chair: Judith Balmaña, ES |
| 90’ | 30’ Recognizing variants of germline origin in tumor sequencing: ESMO guidelines  
Marjolijn Ligtenberg, NL |
|  | 30’ PTEN-hamartoma syndrome  
Nicoline Hoogerbrugge, NL |
|  | 30’ Participants clinical case discussion (2x15’)  
Faculty |
| 19:30 | Dinner |

**Saturday, 30 September 2023**

| 09:00-10:30 | **SESSION 5**  
Hereditary breast and ovarian cancer  
Chair: Nicoline Hoogerbrugge, NL |
| 90’ | 25’ Germline susceptibility to breast and ovarian cancer in 2023  
Marc Tischkowitz, UK |
|  | 25’ How to adapt our clinics to deliver targeted therapies for hereditary breast and ovarian cancer  
Judith Balmaña, ES |
|  | 25’ The role of germline alterations in fertility and reproductive decision making  
Matteo Lambertini, IT |
|  | 15’ Discussion  
Faculty |
| 10:30-11:00 | Coffee break |
| 11:00-12:00 | **SESSION 6**  
Participants clinical case discussion  
Chairs: Judith Balmaña, ES  
Nicoline Hoogerbrugge, NL |
| 60’ | 60’ Participants clinical case discussion (4x15’)  
Faculty |
| 12:00-12:15 | Conclusion and farewell  
Judith Balmaña, ES  
Nicoline Hoogerbrugge, NL |
| 12:15-13:15 | Lunch |

**Note:** Each 15 minutes slot for clinical case discussion includes 7’ case presentation and 8’ Q&A / panel discussion